Neuroimmune and Autoimmune Disorders

A Unifying Framework for Immune-Triggered Regression, Psychiatric-Motor Syndromes, and Neurological Instability

Developed in conjunction with Sylvia Fogel, MD, a psychiatrist affiliated with Massachusetts General Hospital and an instructor at Harvard Medical School, with expertise in psychiatric and neurodevelopmental complexity in autism, including diagnostic differentiation, mood and anxiety disorders, and behavioral regulation within medically complex care. She is also a parent of a son with autism and PANS.

Autism is not one condition.

Roughly 40% of children with autism experience neurodevelopmental regression, most commonly described during toddlerhood or early childhood, although clinicians treating autism report regressive or destabilizing episodes across the life course. These regressions are characterized by abrupt changes in behavior or cognition, movement abnormalities, sleep disturbance, or seizure activity, and often follow infections, immune activation, metabolic stress, or environmental exposures.

The features of neurodevelopmental regression overlap significantly with the symptoms of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). Many clinicians also describe an increasing prevalence of a catatonia-like syndrome, particularly in older adolescents and adults, which may likewise relate to immune triggers or chronic immune dysregulation affecting the central nervous system.

These events are not simply “behavioral episodes.” We propose a model in which neurodevelopmental regression and catatonic states may resemble or overlap with neuroimmune encephalopathy-like processes. These conditions arise when a biologically vulnerable brain encounters an immune or metabolic challenge that exceeds its neuroenergetic capacity, triggering widespread network destabilization.

This page introduces the biological architecture underlying these conditions providing  detailed sub-sections on PANS/PANDAS, Autoimmune Encephalitis, and Catatonia. Some presentations involve defined autoantibodies targeting neural or placental proteins, while others reflect innate immune activation and microglial signaling without a single antibody driver; both pathways can converge on similar neural circuit disruption.

Key Scientific Distinction

    •    Autoimmune = antibody-mediated or adaptive immune specificity
    •    Neuroinflammatory = innate immune / microglial / cytokine-driven

Together, these processes can converge on a neuroimmune encephalopathic state.

Bottom-line: Regression and abrupt functional decline are most often observed when immune activation coincides with periods of high synaptic remodeling, myelination, and metabolic demand, overwhelming neural energy reserves—although immune-mediated brain pathology may contribute to acute or chronic symptoms at any age.

The Shared Biology: Immune–Metabolic–Neurological Convergence

In a subset of individuals with autism, immune activation does not resolve normally, placing sustained metabolic and inflammatory stress on the brain and altering neural function during sensitive developmental windows.

Across these conditions, four systems collide:

1. Immune Activation

Infections, inflammation, autoantibodies, environmental triggers, immune deviations, and maternal immune programming can activate:

  • cytokine cascades
  • microglial responses
  • complement pathways
  • antibody-mediated neuronal signaling interference

2. Mitochondrial Stress & Purinergic Signaling

When the immune system escalates, mitochondria shift into danger mode:

  • decreased ATP availability
  • extracellular ATP release as a distress signal
  • redox imbalance
  • impaired oxidative phosphorylation
  • increased metabolic “load” on sensitive neural circuits

This is core Cell Danger Response (CDR) biology.

3. Microglial Activation & Synaptic Instability

Immune activation pushes microglia into:

  • inflammatory phenotypes
  • excessive synaptic pruning
  • white matter signal changes
  • basal ganglia dysfunction
  • impaired network integration

4. Neuroenergetic Failure

When energy demand exceeds metabolic supply, neurocircuitry fails:

  • motor initiation collapses
  • cortical–basal ganglia loops destabilize
  • electrical thresholds drop, increasing seizure risk
  • frontal circuits narrow, producing OCD-like loops
  • autonomic instability emerges
  • shutdown states (catatonia) appear

Together, these processes can manifest as a neuroimmune encephalopathic event.

Why Some Children Are Vulnerable: Primers

These syndromes disproportionately affect individuals with:

  • mitochondrial fragility
  • redox imbalance
  • microglial priming
  • genetic pathway vulnerabilities
  • folate transport issues
  • autoantibody susceptibility
  • maternal immune activation history
  • chronic GI inflammation
  • metabolic underperformance
  • poor sleep/circadian stress
  • microbiome vulnerabilities

These primers lower the threshold for immune-triggered neurological destabilization.

What Pushes the System Over the Edge: Triggers

Common triggers include:

  • infections (e.g., streptococcal, viral, mycoplasma)
  • fever or inflammatory illness
  • acute or repeated immune activation events in biologically vulnerable children
  • anesthesia
  • toxicant exposures
  • major allergens
  • sleep loss
  • psychological or metabolic stress

Triggers interact with underlying primers, initiating an encephalopathic cascade.

What Sustains the Crisis: Amplifiers

Amplifiers prolong or deepen neurological decline:

  • IL-1β, IL-6, and TNF-α–driven cytokine signaling
  • purinergic ATP signaling
  • glutamate excess with inadequate inhibitory control
  • autoantibody propagation
  • blood–brain barrier permeability
  • oxidative stress
  • autonomic and metabolic dysregulation
  • seizure activity
  • secondary microglial activation

These processes drive the regression, shutdown, neuropsychiatric, motor, or seizure phenotypes observed in affected individuals.

Clinical Phenotypes Seen in Neuroimmune Encephalopathies

Depending on the circuits affected, the child may present with:

  • sudden or accelerated regression
  • abrupt loss of skills
  • motor deterioration (stiffness, freezing, dystonia, compulsive movements)
  • OCD-like looping
  • dramatic eating restriction
  • emotional lability
  • autonomic instability
  • catatonia
  • seizure onset or worsening
  • cognitive slowing or fog
  • sensory amplification
  • urinary frequency or other autonomic symptoms

Bottom Line: Clinical findings routinely indicate that neurodevelopmental regressions are not purely behavioral phenomena or psychiatric constructs; these are often biological events, driven by complex immune, metabolic, and neurological interactions.

PANS / PANDAS

Immune-Triggered Basal Ganglia Dysfunction and Abrupt Neuropsychiatric Regression

PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus) and its broader spectrum, PANS (Pediatric Acute-onset Neuropsychiatric Syndrome), share important clinical and biological features with neurodevelopmental regression (NDR) observed in a subset of individuals with autism.

PANS/PANDAS are post-infectious neuroimmune syndromes characterized by acute-onset neuropsychiatric and neurological symptoms following immune activation in biologically vulnerable children. In some individuals with autism, similar immune-triggered mechanisms may contribute to, overlap with, or be clinically indistinguishable from sudden neuropsychiatric deterioration, loss of adaptive functioning, or regression of previously acquired skills.

Both PANS/PANDAS and immune-associated regression in autism may present with abrupt behavioral change, marked personality shift, anxiety, emotional lability, cognitive disruption, movement abnormalities, sleep disturbance, or loss of functional skills. While PANS/PANDAS also occur in individuals without autism, clinical reports and emerging studies suggest overlapping vulnerability profiles in some children diagnosed with autism who experience immune-triggered regression.

Biological Conceptualization

PANS and PANDAS can be conceptualized as basal ganglia–centered neuroimmune encephalopathy-like syndromes, in which immune signaling disrupts cortico–striatal–thalamo–cortical circuits governing emotion regulation, movement, behavior, and cognitive flexibility.

Rather than representing primary psychiatric illness, these presentations reflect immune–metabolic disruption of neural networks, particularly in children with underlying neurobiological vulnerability.

Primers: Why Some Children Are Susceptible

Affected individuals frequently demonstrate biological features that lower the threshold for immune-triggered neurological destabilization, including:

  • microglial priming from early stress or infection
  • redox imbalance (low glutathione, high oxidative stress)
  • mitochondrial inefficiency
  • folate transport or methylation vulnerabilities
  • maternal immune activation exposure
  • genetic pathways affecting immune regulation
  • gastrointestinal inflammation with systemic cytokine signaling
  • microbiome alterations influencing immune tone

These primers reduce neuroenergetic resilience and increase susceptibility to acute immune-mediated disruption.

Triggers: What Initiates Acute Episodes

PANDAS

  • Group A streptococcal infection
  • Autoantibody cross-reactivity against basal ganglia proteins

PANS

  • Viral or bacterial infections
  • Febrile or inflammatory illness
  • Immune activation events
  • Allergic or inflammatory flares
  • Environmental immune stressors
  • Medical immune activation events that induce acute metabolic, inflammatory or cytokine responses in biologically vulnerable children
  • Significant metabolic or psychological stress

In susceptible individuals, these triggers may initiate acute neuroimmune cascades rather than resolving normally.

Amplifiers: How Symptoms Escalate

Once initiated, a combination of immune, metabolic, and neural processes can amplify symptom severity:

  • inflammatory cytokines altering synaptic signaling
  • extracellular ATP release and purinergic danger signaling
  • glutamate excess with impaired inhibitory control
  • basal ganglia inflammation driving motor and compulsive behaviors
  • autoantibody-mediated neuronal signaling disruption
  • transient loss of neuroplasticity

These processes can sustain or deepen regression, neuropsychiatric instability, or motor dysfunction.

Clinical Presentation

Depending on the circuits involved, individuals may present with:

  • abrupt-onset OCD-like behaviors
  • severe emotional lability
  • regression or loss of skills
  • motor abnormalities (chorea, dystonia, handwriting deterioration)
  • sensory amplification
  • urinary frequency or urgency
  • sleep disruption
  • cognitive slowing or “brain fog”
  • sudden restrictive eating
  • acute or escalating anxiety

Although these symptoms often resemble primary psychiatric conditions, their biological signature reflects immune–metabolic–neurological disruption.

Autoimmune Encephalitis & Autoantibody-Related Brain Disorders

Immune-Mediated Neural Dysfunction Across Development

Autoimmune Encephalitis (AE) encompasses a spectrum of immune-mediated brain disorders in which autoantibodies and/or other immune mechanisms—including immune complexes, complement activation, and inflammatory cytokines—disrupt neuronal signaling and synaptic integrity.

AE is a formal diagnostic entity with established criteria that may or may not be met in presentations of autism with neurodevelopmental regression. In such cases, the broader descriptive framework of neuroimmune encephalopathy may be more applicable. Nonetheless, the scientific literature on AE provides important mechanistic and clinical insights into immune-mediated neural dysfunction relevant to autism with regression and related neuroimmune syndromes.

Subtypes of Autoantibody-Related Brain Disorders Relevant to Autism

1. Maternal Autoantibody-Related Autism (MAR Autism)

Maternal autoantibodies targeting fetal brain proteins (e.g., CRMP1, CRMP2, STIP1) are associated with:

  • altered cortical development
  • synaptic patterning disruptions
  • immune priming
  • higher rates of severe autism phenotypes
  • distinct behavioral and neuroanatomical features

2. Folate Receptor Autoantibodies (FRAA)

Blocking folate transport leads to:

  • cerebral folate deficiency
  • impaired methylation
  • mitochondrial dysfunction
  • developmental regression
  • irritability, agitation, sleep disruption
  • language deficits

3. Post-Infectious Autoimmune Encephalitis

Immune activation triggers:

  • anti-neuronal autoantibodies
  • basal ganglia inflammation
  • regression or cognitive decline
  • neuropsychiatric symptoms
  • seizure activity

Shared Mechanistic Pathways

Across these neuroimmune subtypes, common biological processes include:

  • antibody-mediated disruption of neuronal function
  • complement-associated synaptic injury
  • cytokine-driven microglial activation
  • purinergic dysregulation after ATP release
  • mitochondrial and metabolic collapse under inflammatory load

Together, these mechanisms may represent important medical contributors to neurodevelopmental instability and regression in a biologically susceptible subset of individuals.

Catatonia: Neuroenergetic Shutdown

When Mitochondria, Immune Signaling, and Network Integration Fail

In autism and related neuroimmune conditions, catatonia is frequently described in psychiatric terms despite evidence that, in some individuals, it may reflect underlying immune, metabolic, and synaptic dysfunction.

Mechanisms

  • mitochondrial energy crisis impairing movement initiation
  • cytokine-induced network freezing
  • impaired inhibitory control with glutamatergic dominance
  • purinergic signaling–mediated circuit narrowing
  • fronto–striatal network disconnection
  • severe oxidative stress leading to metabolic collapse

Phenotype

  • freezing or immobility
  • posturing
  • mutism
  • slowed responses
  • repetitive or purposeless movement
  • alternating stupor and agitation
  • autonomic instability
  • regression of previously acquired skills

Catatonia may emerge following immune or metabolic stressors, including infection, inflammation, seizure clusters, or neuroimmune flares.

Catatonia should be evaluated as a potential danger-state physiology with immune–metabolic contributors, alongside appropriate symptomatic stabilization and medical investigation.

Bottom Line: PANS/PANDAS, autoimmune encephalopathies, immune-associated regression, and catatonia represent overlapping immune–metabolic–neurological syndromes, rather than isolated behavioral or psychiatric phenomena. Recognizing their shared biological architecture is essential for accurate diagnosis, appropriate medical evaluation, and the development of targeted, mechanism-informed interventions.

References

Immune dysregulation, neuroimmune mechanisms, and GI–immune axis

Erbescu, A., Papuc, S. M., Budisteanu, M., Arghir, A., & Neagu, M. (2022). Re-emerging concepts of immune dysregulation in autism spectrum disorders. Frontiers in psychiatry, 13, 1006612. https://doi.org/10.3389/fpsyt.2022.1006612 PMID: 36339838

McLellan, J., Kim, D. H. J., Bruce, M., Ramirez-Celis, A., & Van de Water, J. (2022). Maternal Immune Dysregulation and Autism-Understanding the Role of Cytokines, Chemokines and Autoantibodies. Frontiers in psychiatry, 13, 834910. https://doi.org/10.3389/fpsyt.2022.834910 PMID: 35722542

Frasch, M. G., Yoon, B. J., Helbing, D. L., Snir, G., Antonelli, M. C., & Bauer, R. (2023). Autism Spectrum Disorder: A Neuro-Immunometabolic Hypothesis of the Developmental Origins. Biology, 12(7), 914. https://doi.org/10.3390/biology12070914 PMID: 37508346 

Moreno, R. J., Rose, D. R., Tancredi, D. J., Schmidt, R. J., Ozonoff, S. J., & Ashwood, P. (2024). Cord blood cytokine profiles in children later diagnosed with autism spectrum disorder: Results from the prospective MARBLES study. Brain, behavior, and immunity, 122, 339–344. https://doi.org/10.1016/j.bbi.2024.08.036 PMID: 39163910

Whiteley, P., Marlow, B., Kapoor, R. R., Blagojevic-Stokic, N., & Sala, R. (2021). Autoimmune Encephalitis and Autism Spectrum Disorder. Frontiers in psychiatry, 12, 775017. https://doi.org/10.3389/fpsyt.2021.775017 PMID: 34975576

H.K. Hughes, R.J.Moreno, P. Ashwood, Innate immune dysfunction and neuroinflammation in autism spectrum disorder (ASD), Brain, Behavior, and Immunity, Volume 108, 2023, Pages 245-254, ISSN 0889-1591, https://doi.org/10.1016/j.bbi.2022.12.001.

PANDAS / PANS

Vreeland, A., Thienemann, M., Cunningham, M., Muscal, E., Pittenger, C., & Frankovich, J. (2023). Neuroinflammation in Obsessive-Compulsive Disorder: Sydenham Chorea, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections, and Pediatric Acute Onset Neuropsychiatric Syndrome. *Psychiatric clinics of North America*, 46(1), 69-88. https://doi.org/10.1016/j.psc.2022.11.004  PMID: 36740356

Gagliano, A., Carta, A., Tanca, M. G., & Sotgiu, S. (2023). Pediatric Acute-Onset Neuropsychiatric Syndrome: Current Perspectives. *Neuropsychiatric disease and treatment*, 19, 1221-1250. https://doi.org/10.2147/NDT.S362202  PMID: 37251418

Vreeland, A., Calaprice, D., Or-Geva, N., Frye, R. E., Agalliu, D., Lachman, H. M., Pittenger, C., Pallanti, S., Williams, K., Ma, M., Thienemann, M., Gagliano, A., Mellins, E., & Frankovich, J. (2023). Postinfectious Inflammation, Autoimmunity, and Obsessive-Compulsive Disorder: Sydenham Chorea, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection, and Pediatric Acute-Onset Neuropsychiatric Disorder. *Developmental neuroscience*, 45(6), 361-374. https://doi.org/10.1159/00053426  PMID: 37742615

Wells, L., O’Hara, N., Frye, R. E., Hullavard, N., & Smith, E. (2024). Folate Receptor Alpha Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) Population. *Journal of personalized medicine*, 14(2), 166. https://doi.org/10.3390/jpm14020166  PMID: 38392599

Leonardi, L., Perna, C., Bernabei, I., Fiore, M., Ma, M., Frankovich, J., Tarani, L., & Spalice, A. (2024). Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS): Immunological Features Underpinning Controversial Entities. Children (Basel, Switzerland), 11(9), 1043. https://doi.org/10.3390/children11091043 PMID: 39334578

Ma M, Masterson EE, Gao J, et al. Development of Autoimmune Diseases Among Children With Pediatric Acute-Onset Neuropsychiatric Syndrome. JAMA Netw Open. 2024;7(7):e2421688. doi:10.1001/jamanetworkopen.2024.21688 (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2821657)

Rogers, J. P., Pollak, T. A., Blackman, G., & David, A. S. (2019). Catatonia and the immune system: a review. The lancet. Psychiatry, 6(7), 620–630. https://doi.org/10.1016/S2215-0366(19)30190-7 PMID: 31196793

Treatment with Leucovorin

Frye, R. E., Slattery, J., Delhey, L., Furgerson, B., Strickland, T., Tippett, M., Sailey, A., Wynne, R., Rose, S., Melnyk, S., Jill James, S., Sequeira, J. M., & Quadros, E. V. (2018). Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. *Molecular psychiatry*, 23(2), 247-256. https://doi.org/10.1038/mp.2016.168  PMID: 27752075

Panda, P. K., Sharawat, I. K., Saha, S., Gupta, D., Palayullakandi, A., & Meena, K. (2024). Efficacy of oral folinic acid supplementation in children with autism spectrum disorder: a randomized double-blind, placebo-controlled trial. *European journal of pediatrics*, 183(11), 4827-4835. https://doi.org/10.1007/s00431-024-05762-6  PMID: 39243316

Batebi, N., Moghaddam, H. S., Hasanzadeh, A., Fakour, Y., Mohammadi, M. R., & Akhondzadeh, S. (2021). Folinic Acid as Adjunctive Therapy in Treatment of Inappropriate Speech in Children with Autism: A Double-Blind and Placebo-Controlled Randomized Trial. *Child psychiatry and human development*, 52(5), 928-938. https://doi.org/10.1007/s10578-020-01072-8  PMID: 33029705

Renard, E., Leheup, B., Gueant-Rodriguez, R. M., Oussalah, A., Quadros, E. V., & Gueant, J. L. (2020). Folinic acid improves the score of Autism in the EFFET placebo-controlled randomized trial. *Biochimie*, 173, 57-61. https://doi.org/10.1016/j.biochi.2020.04.019 PMID: 32387472

Meltzer, A., Van de Water, J. The Role of the Immune System in Autism Spectrum Disorder. Neuropsychopharmacol 42, 284–298 (2017). https://doi.org/10.1038/npp.2016.158